GLP-1 gene ther­a­py trig­gers 25% weight loss in obese mice, clin­i­cal tri­als planned for next year

One of the biggest prob­lems fac­ing the bur­geon­ing class of weight loss drugs is that peo­ple must take them day af­ter day, week af­ter week. When the in­jec­tions of semaglu­tide — the in­gre­di­ent in Ozem­pic and We­govy — stop com­ing, so do the ben­e­fits. Lost weight is re­gained.

But re­searchers at Fractyl Health, a Lex­ing­ton, MA-based biotech, be­lieve they have a so­lu­tion to that prob­lem: a one-time gene ther­a­py in­ject­ed in­to the pan­creas that lets the body make its own GLP-1 ag­o­nists in per­pe­tu­ity.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER